Skip to content
Screener

Tandem Diabetes Care TNDM Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue$240.7MMiss by $9.5M
EPS-$0.48Miss by $0.08
Revenue estimate$250.2M
EPS estimate-$0.40

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$266.1M
EPS estimate-$0.26

Financials

Q2 2025

Income statement

See full
Revenue$240.7M+8.5%
Gross profit$125.9M+11.6%
Operating income-$51.8M-68.4%
Net income-$52.4M-70.1%
EPS (diluted)-$0.78-66.0%

Balance sheet

See full
Cash & equivalents$64.1M+34.4%
Total debt$449.0M-13.3%
Total equity$133.3M-43.0%
Total assets$875.7M-6.6%

Cash flow

See full
Operating cash flow-$9.5M-80.0%
CapEx$6.2M-4.0%
Free cash flow-$15.7M-33.7%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.34B-48.3%
Enterprise value$1.73B-43.7%
P/S1.3×-1.9×

Profitability

See full
Gross margin52.5%+3.5pp
Operating margin-19.9%+3.2pp
Net margin-20.5%+5.0pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-111.9%-475pp
Debt / equity3.4×+1.2×
Current ratio2.4×-0.6×

Segments

By product

See full
Supplies and other$128.8M+13.1%
Pump$111.9M+3.7%

FAQ

When did Tandem Diabetes Care report Q2 2025 earnings?
Tandem Diabetes Care (TNDM) reported Q2 2025 earnings on August 6, 2025 after market close.
What were Tandem Diabetes Care's Q2 2025 revenue and EPS?
Tandem Diabetes Care reported revenue of $240.7M and eps of $-0.48 for Q2 2025.
Did Tandem Diabetes Care beat estimates in Q2 2025?
Revenue missed the consensus estimate of $250.2M by $9.5M. EPS missed the consensus estimate of $-0.40 by $0.08.
How did Tandem Diabetes Care's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 8.5% from $221.9M a year earlier and eps declined 2.1% from $-0.47.
Where can I find Tandem Diabetes Care's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001438133-25-000155) and the 10-Q periodic report (0001438133-25-000157) directly on SEC EDGAR. The filing index links above go to sec.gov.